Last reviewed · How we verify

Placebo to Formoterol

Novartis · Phase 3 active Small molecule

Placebo to Formoterol is a Long-acting beta-2 agonist (LABA) Small molecule drug developed by Novartis. It is currently in Phase 3 development for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.

Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Generic namePlacebo to Formoterol
SponsorNovartis
Drug classLong-acting beta-2 agonist (LABA)
TargetBeta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaRespiratory
PhasePhase 3

Mechanism of action

Formoterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels, leading to smooth muscle relaxation and sustained bronchodilation. This mechanism provides rapid onset (within minutes) and long duration of action (12+ hours), making it suitable for maintenance therapy in obstructive airway diseases. The drug also has anti-inflammatory effects on airway tissues.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo to Formoterol

What is Placebo to Formoterol?

Placebo to Formoterol is a Long-acting beta-2 agonist (LABA) drug developed by Novartis, indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

How does Placebo to Formoterol work?

Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.

What is Placebo to Formoterol used for?

Placebo to Formoterol is indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Who makes Placebo to Formoterol?

Placebo to Formoterol is developed by Novartis (see full Novartis pipeline at /company/novartis).

What drug class is Placebo to Formoterol in?

Placebo to Formoterol belongs to the Long-acting beta-2 agonist (LABA) class. See all Long-acting beta-2 agonist (LABA) drugs at /class/long-acting-beta-2-agonist-laba.

What development phase is Placebo to Formoterol in?

Placebo to Formoterol is in Phase 3.

What are the side effects of Placebo to Formoterol?

Common side effects of Placebo to Formoterol include Tremor, Headache, Palpitations, Muscle cramps, Nervousness, Tachycardia.

What does Placebo to Formoterol target?

Placebo to Formoterol targets Beta-2 adrenergic receptor and is a Long-acting beta-2 agonist (LABA).

Related